Know Cancer

forgot password

A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer

Phase 3
18 Years
Not Enrolling
Breast Cancer, Colorectal Cancer, Pain

Thank you

Trial Information

A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer


- Determine the efficacy of celecoxib in reducing the incidence and severity of hand/foot
syndrome caused by capecitabine in patients with metastatic breast cancer or colorectal

OUTLINE: This is a placebo-controlled, randomized, double-blind, multicenter study. Patients
are stratified according to metastatic disease (breast vs colorectal), ECOG performance
status (0 or 1 vs 2), prior chemotherapy (yes vs no).

Patients receive 1 of 2 treatment regimens.

- Regimen A (concurrent radiotherapy): Patients undergo radiotherapy 5 days a week for
5-6 weeks and receive oral capecitabine twice daily 5 days a week. Following completion
of radiotherapy, patients may continue oral capecitabine as in regimen B.

- Regimen B (no radiotherapy): Patients receive oral capecitabine once daily on days
1-14. Courses repeat every 21 days.

Patients are also randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral celecoxib twice daily on days 1-21.

- Arm II: Patients receive oral placebo twice daily on days 1-21. In both arms, treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 342 patients will be accrued for this study.

Inclusion Criteria:

1. Patients with metastatic colorectal cancer or breast cancer who are scheduled*** to
receive capecitabine with an initial dose in the range of 750-1500 mg/m2** twice
daily (total daily dose in the range of 1500-3000 mg/m2) alone or in combination with
one or more other agents. ***Patients may enter the study after having received
capecitabine for up to 21 days prior to study entry. **Doses may be rounded upward or
downward per physician discretion to utilize 500mg tablets.

2. Patients with either metastatic colorectal or metastatic breast cancer may have
received any number or type of prior treatment regimens for metastatic disease or
they may have received no prior treatment for metastatic disease.

3. Men and women from all ethnic and racial groups.

4. >/= 18 years old

5. ECOG Performance Status
6. Adequate organ function: a. Total bilirubin limits (IUNL) b. AST (SGOT) and/or ALT (SGPT) mets AST/(SGOT) and/or ALT(SGPT) < 5 x IUNL d. Alkaline phosphatase Creatinine Clearance > 50 ml/min

7. Adequate bone marrow function: (a) Leukocytes >/= 3,000/microL; (b) Absolute
neutrophil count >/= 1,500/microL; (c) Platelets >/= 100,000/microL

8. Women of childbearing age and all men must agree to use adequate contraception
(hormonal or barrier method of birth control) prior to study entry and for the
duration of study participation.

9. Negative pregnancy test for women of childbearing age.

10. Must have the ability to understand and the willingness to provide a written informed
consent to participate in the study.

11. Controlled brain metastasis (i.e. stereotactic surgery, surgery steroids,

Exclusion Criteria:

1. History of allergies to sulfonamide, aspirin, any NSAID or 5FU or any COX-2

2. Any regular use of COX-2 inhibitors, NSAIDS or aspirin >325 mg more than twice a

3. Pregnancy or lactation.

4. History of significant neurological or psychiatric disorders that would impede giving
consent, treatment or follow-up.

5. Any serious illness or medical condition: uncontrolled congestive heart failure,
uncontrolled hypertension or arrhythmia, active angina pectoris, any history of
myocardial infarction, stroke or TIA

6. Serious uncontrolled active infection.

7. Patients who cannot comply with taking and documenting oral study medications.

8. History of active peptic ulcer disease or upper GI bleed within 12 months of

9. Use of warfarin.

10. Patients with uncontrolled brain metastasis.

11. Patients may have had prior HFS but it must be completely resolved for >/= 4 weeks.

12. No concurrent radiation therapy.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care

Outcome Measure:

Incidence of hand/foot syndrome (HFS) > grade 1 as assessed by NCI CTC v3.0 criteria at 16 weeks

Outcome Time Frame:

Interim analysis at 16 Weeks, with evaluations and blood test every 3 weeks.

Safety Issue:


Principal Investigator

Scott Kopetz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Federal Government

Study ID:




Start Date:

January 2006

Completion Date:

November 2008

Related Keywords:

  • Breast Cancer
  • Colorectal Cancer
  • Pain
  • Hand-Foot Syndrome
  • cancer-related problem/condition
  • drug/agent toxicity by tissue/organ
  • pain
  • palmar-plantar erythrodysesthesia
  • stage IV breast cancer
  • male breast cancer
  • recurrent breast cancer
  • stage IV colon cancer
  • stage IV rectal cancer
  • recurrent colon cancer
  • recurrent rectal cancer
  • Celecoxib
  • Celebrex
  • Capecitabine
  • Xeloda
  • Breast Neoplasms
  • Colorectal Neoplasms



CCOP - Kansas City Kansas City, Missouri  64131
CCOP - Kalamazoo Kalamazoo, Michigan  49007-3731
Marshfield Clinic - Marshfield Center Marshfield, Wisconsin  54449
CCOP - Santa Rosa Memorial Hospital Santa Rosa, California  95403
Cancer Research for the Ozarks Springfield, Missouri  65807
CCOP - Columbus Columbus, Ohio  43206
CCOP - Greenville Greenville, South Carolina  29615
CCOP - Grand Rapids Grand Rapids, Michigan  49503
CCOP - Northwest Tacoma, Washington  98405-0986
M. D. Anderson Cancer Center at University of Texas Houston, Texas  77030-4009
CCOP - Main Line Health Wynnewood, Pennsylvania  19096
Scott and White Cancer Institute Temple, Texas  76508
Hematology Oncology Associates of Central New York, PC - Northeast Center East Syracuse, New York  13057-4510